Table 5.
Nucleotide metabolites in bladder cancer.
| Study | Sample type | Analytical platform | Purine |
Pyrimidine |
|||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Adenine | Guanine | Cytosine | Thymine | Uridine | Uracil | Inosine | Hypoxanthine | Ribose | |||
| Pasikanti et al., 2010 [22] | Urine | GC/TOFMS | ↑ | ||||||||
| Putluri et al., 2011 [24] | Urine | LC-MS | ↑ | ↑ | ↑ | ||||||
| Tripathi et al., 2013 [35] | Tissue | H-NMR, GC-MS | ↑ | ||||||||
| Pasikanti et al., 2013 [29] | Urine | GC×GC-TOFMS | ↑ | ↑ | |||||||
| Peng et al., 2014 [34] | Urine | LC-MS | ↓ | ||||||||
| Wittmann et al., 2014 [36] | Urine | UHPLC-MS/MS GC-MS | ↓ | ↑ | |||||||
| Zhou et al., 2016 [38] | Plasma | GC-MS-SIM | ↑ | ↓ | ↑ | ||||||
| Tan et al., 2017 [39] | Serum | UHPLC-Q-TOFMS | ↑ | ↑ | |||||||
| Yumba Mpanga et al., 2018 [41] | Urine | RP-HPLC-QQQ/MS | ↑ | ||||||||
| Jacyna et al., 2019 [43] | Urine | MS, H-NMR | ↑ | ||||||||
| Lin et al., 2021 [46] | Urine | GC-MS | ↑ | ||||||||
| Li et al., 2022 [49] | Urine | LC-MS | ↓ | ||||||||
| Jacyna et al., 2022 [50] | Urine | MS, H-NMR | ↑↓ | ||||||||
GC, gas chromatography; MS, mass spectrometry; TOFMS, time-of-flight MS; LC, liquid chromatography; H-NMR, proton nuclear magnetic resonance; UHPLC-MS/MS, ultrahigh-performance liquid chromatography/tandem MS; SIM, selected ion monitoring; UHPLC-QTOFMS, UHPLC-quadrupole TOFMS; RP-HPLC-QQQ/MS, reverse-phase high-performance liquid chromatography coupled with triple quadrupole MS. ↓, downregulated; ↑, upregulated; ↓↑, undetermined trend.